Suppr超能文献

心脏标志物对 COVID-19 患者风险分层和管理的影响。

Implications of cardiac markers in risk-stratification and management for COVID-19 patients.

机构信息

Department of Bioinformatics, Nanjing Medical University, Nanjing, China.

Department of Geriatrics, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

出版信息

Crit Care. 2021 Apr 26;25(1):158. doi: 10.1186/s13054-021-03555-z.

Abstract

BACKGROUND

COVID-19 has resulted in high mortality worldwide. Information regarding cardiac markers for precise risk-stratification is limited. We aim to discover sensitive and reliable early-warning biomarkers for optimizing management and improving the prognosis of COVID-19 patients.

METHODS

A total of 2954 consecutive COVID-19 patients who were receiving treatment from the Wuhan Huoshenshan Hospital in China from February 4 to April 10 were included in this retrospective cohort. Serum levels of cardiac markers were collected after admission. Coronary artery disease diagnosis and survival status were recorded. Single-cell RNA-sequencing and bulk RNA-sequencing from different cohorts of non-COVID-19 were performed to analyze SARS-CoV-2 receptor expression.

RESULTS

Among 2954 COVID-19 patients in the analysis, the median age was 60 years (50-68 years), 1461 (49.5%) were female, and 1515 (51.3%) were severe/critical. Compared to mild/moderate (1439, 48.7%) patients, severe/critical patients showed significantly higher levels of cardiac markers within the first week after admission. In severe/critical COVID-19 patients, those with abnormal serum levels of BNP (42 [24.6%] vs 7 [1.1%]), hs-TNI (38 [48.1%] vs 6 [1.0%]), α- HBDH (55 [10.4%] vs 2 [0.2%]), CK-MB (45 [36.3%] vs 12 [0.9%]), and LDH (56 [12.5%] vs 1 [0.1%]) had a significantly higher mortality rate compared to patients with normal levels. The same trend was observed in the ICU admission rate. Severe/critical COVID-19 patients with pre-existing coronary artery disease (165/1,155 [10.9%]) had more cases of BNP (52 [46.5%] vs 119 [16.5%]), hs-TNI (24 [26.7%] vs 9.6 [%], α- HBDH (86 [55.5%] vs 443 [34.4%]), CK-MB (27 [17.4%] vs 97 [7.5%]), and LDH (65 [41.9%] vs 382 [29.7%]), when compared with those without coronary artery disease. There was enhanced SARS-CoV-2 receptor expression in coronary artery disease compared with healthy controls. From regression analysis, patients with five elevated cardiac markers were at a higher risk of death (hazards ratio 3.4 [95% CI 2.4-4.8]).

CONCLUSIONS

COVID-19 patients with pre-existing coronary artery disease represented a higher abnormal percentage of cardiac markers, accompanied by high mortality and ICU admission rate. BNP together with hs-TNI, α- HBDH, CK-MB and LDH act as a prognostic biomarker in COVID-19 patients with or without pre-existing coronary artery disease.

摘要

背景

COVID-19 在全球范围内导致了高死亡率。有关心脏标志物的信息对于精确的风险分层有限。我们旨在发现敏感和可靠的预警生物标志物,以优化管理并改善 COVID-19 患者的预后。

方法

本回顾性队列研究纳入了 2020 年 2 月 4 日至 4 月 10 日期间在中国武汉火神山医院接受治疗的 2954 例连续 COVID-19 患者。入院后采集血清心脏标志物水平。记录冠心病诊断和生存状态。对不同非 COVID-19 队列进行单细胞 RNA 测序和批量 RNA 测序,以分析 SARS-CoV-2 受体表达。

结果

在分析的 2954 例 COVID-19 患者中,中位年龄为 60 岁(50-68 岁),1461 例(49.5%)为女性,1515 例(51.3%)为重症/危重症。与轻症/中度(1439 例,48.7%)患者相比,重症/危重症患者在入院后第一周内的心脏标志物水平明显更高。在重症/危重症 COVID-19 患者中,BNP(42[24.6%] vs. 7[1.1%])、hs-TNI(38[48.1%] vs. 6[1.0%])、α-HBDH(55[10.4%] vs. 2[0.2%])、CK-MB(45[36.3%] vs. 12[0.9%])和 LDH(56[12.5%] vs. 1[0.1%])血清水平异常的患者死亡率明显更高。这种趋势也反映在 ICU 入院率上。患有冠心病的重症/危重症 COVID-19 患者(165/1155[10.9%])BNP(52[46.5%] vs. 119[16.5%])、hs-TNI(24[26.7%] vs. 9.6[16.5%])、α-HBDH(86[55.5%] vs. 443[34.4%])、CK-MB(27[17.4%] vs. 97[7.5%])和 LDH(65[41.9%] vs. 382[29.7%])的病例更多。与无冠心病患者相比,冠心病患者 SARS-CoV-2 受体表达增强。从回归分析来看,五种心脏标志物升高的患者死亡风险更高(风险比 3.4[95%CI 2.4-4.8])。

结论

患有冠心病的 COVID-19 患者表现出更高比例的心脏标志物异常,伴有高死亡率和 ICU 入院率。BNP 联合 hs-TNI、α-HBDH、CK-MB 和 LDH 可作为 COVID-19 患者(无论是否存在冠心病)的预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cd1/8077943/100349bf1286/13054_2021_3555_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验